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Symposium: Around organs / combination therapy: Gut  
SP-0029   
GI consequences of cancer treatment: the past, the 
present and the future: a clinical perspective 
J. Andreyev1 
1The Royal Marsden NHS Foundation Trust, The GI Unit, 
London, United Kingdom   
Toxicity is an inevitable consequence of cancer treatment.   
While patients want curative treatment if possible, quality of 
life issues have been somewhat neglected in the race to 
improve survival.   Patient reported outcome measures 
(PROMS) confirm that most routinely used clinical scoring 
systems fail to identify important toxicities and as a result 
the frequency, severity and impact on patients’ lives of 
chronic GI consequences of cancer therapies has historically 
not been fully recognised by clinicians.   Nor has it received 
the attention that it deserves in terms of research.  Yet the 
iatrogenically driven morbidity of cancer treatments and 
especially radiotherapy is an important human model of GI 
disease and has already yielded new insights which can be 
applied to benign and malignant diseases. 
In the last 20 years, a largely unheralded but spectacular 
revolution in understanding why toxicity develops, how it 
should be identified, measured and managed has gathered 
speed.   Inaccurate terminology describing toxicity in the 
past has significantly hindered progress.  It is now recognised 
that toxicities rarely affect just one organ system and the 
concept that toxicities after radical treatment are a 
progressive disease, Pelvic Radiation Disease, have helped 
formulate more productive treatment approaches and 
understand future priorities.  Clinical studies now show that 
applying this new understanding allows much GI toxicity 
previously widely regarded as incurable to be ameliorated.  
In addition, biomarkers of radiation toxicity – fibrotic markers 
which can be measured in blood are the most promising – 
offer a much more accurate method of detecting toxicity 
than the current approach of defining toxicity by a change in 
symptoms and this is starting to allow new methods of 
preventing toxicity, to be targeted more accurately.   
It is also increasingly understood that the “consequential 
effect” has a critical role in the development of chronic 
toxicity and that it is driven by factors beyond the control of 
the oncologist. One of the most important of these is the 
composition of the gut microbiota; another is the role of the 
immune system.  Introducing techniques already used by 
other disciplines to manipulate these factors will deliver 
future great rewards in terms of reducing chronic toxicity. 
GI toxicity is a major limiting factor to the advance of 
oncological treatments.  Many new solutions have emerged 
but require the harnessing of a multidisciplinary approach in 
a way that oncology has rarely used up to this point.   
SP-0030   
Having guts: saving the organ 
M. Berbée1 
1MAASTRO Clinic, Radiation Oncology, Maastricht, The 
Netherlands  
Intestinal radiation injury may severely hamper quality of life 
during and after treatment of abdominal tumors. Even though 
novel technical advances in treatment delivery have enabled 
more selective irradiation of the tumor, normal tissue 
radiation injury remains the most important dose limiting 
factor of radiotherapy. Hence, there is an urgent need for 
agents that can be administered during radiotherapy to 
prevent and/or reduce radiation-induced intestinal injury. 
These agents should of course not hamper the anti-tumor 
effect of radiation and, ideally, even improve radiation-
induced tumor cell kill.  
Pre-clinical studies have shown that the novel Somatostatin 
analogue Pasireotide effectively reduces radiation-induced 
intestinal injury by preventing post-irradiation pancreatic 
enzyme-dependent intestinal auto-digestion. In our 
experiments Pasireotide was shown to preserve the intestinal 
mucosal surface and to prevent intestinal bacterial 
translocation after radiation exposure. Pasireotide did not 
protect the intestinal stem cells and the beneficial effect of 
Pasireotide could be reversed by pancreatic enzyme 
substitution.  Therefore, Pasireotide does not seem to act as 
a cytoprotector, but to mitigate intestinal radiation injury by 
inhibiting pancreatic exocrine secretion.  
Until recent, knowledge on the effects of Pasireotide on the 
radiation-induced tumor response was scarce or non-existing 
at all. Pre-clinical studies have shown that Pasireotide may 
have a direct inhibiting effect on the growth of certain 
tumors such as neuroendocrine cancers. Moreover, it may 
reduce tumor growth by reducing the availability of growth 
factors such as IGF-1 and VEGF. However, no studies have 
been performed to assess the effect of Pasireotide on 
radiation-induced tumor growth delay. As Pasireotide can 
only be considered for clinical use if it does not hamper the 
anti-tumor effect of radiotherapy, we tested the effect of 
Pasireotide on tumor response to radiation in an animal 
model. The results of this recently performed study may 
enable a trial to test the potential beneficial effect on 
intestinal radiation injury in patients.  
SP-0031   
Radiation induced proctopathy: lessons learned from 
prospective clinical trials 
J. Denham1 
1Calvary Mater Newcastle, Radiation Oncology, Newcastle, 
Australia  
The increasing number of dose escalation and 
hypofractionation prostate cancer trials is providing us 
excellent opportunities to learn more about ano-rectal, 
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bladder base and urethral radiation injuries. Our ability to 
predict these injuries prior to radiotherapy remains limited, 
however. For example, rectal dose volumes are a widely used 
planning tool, but published relationships between irradiated 
volumes and outcomes are inconsistent. 
The presentation is a strictly clinical overview of the factors 
that contribute to ano-rectal radiation injuries and outlines 
recent progress in their management. Symptomatology 
resulting from rarely cited injuries, such as to the per-rectal 
fat and the pelvic floor musculature, are also discussed. 
 
 
Symposium with Proffered Papers: Immobilisation, 
localisation and verification during image guided 
brachytherapy  
 
 
SP-0032   
Influence of immobilisation and implant stability during 
brachytherapy 
B. Pieters1 
1Academic Medical Center, Radiation Oncology, Amsterdam, 
The Netherlands 
 
Abstract not received. 
   
SP-0033   
Role of target and applicator localisation under treatment 
delivery conditions 
T.P. Hellebust1 
1Oslo University Hospital - The Norwegian Radium Hospital, 
Department of Medical Physics, Oslo, Norway  
 
Since the last 10 years 3D image-guided brachytherapy using 
CT, MRI, and/or ultrasound (US) has been introduced into 
clinical practice worldwide enabling conformation of the 
dose distribution to the target volume and avoidance of high 
dose to organs at risk (OAR). To be able to optimise the dose 
distribution in brachytherapy both the anatomy (target 
volume/OAR) and the applicator(s) should be correctly 
localised in the images. If the image modality does not 
enables both of these criteria the dose delivered the patient 
may be calculated incorrectly. Another important aspect is 
that the images should reflect the true situation at the time 
of the treatment. Due to the large dose gradient in 
brachytherapy, even small changes in the position of the 
applicator and/or anatomical structures may lead to 
discrepancies between planned and delivered dose. Usually, 
this is achieved with as short time as possible between 
imaging and treatment delivery. 
The optimal image modality to use is depending on the site 
to be treated as well as the geometry and the material of the 
applicator. For cervical cancer MR imaging is the optimal 
modality to discriminate soft tissue and tumour. Concepts for 
image guided cervical brachytherapy have been developed by 
GEC-ESTRO and T2 weighted MR imaging is the preferred 
modality. In an interobserver study the mean inter-
delineation distance of around 4 mm were found for the high 
risk CTV (HR CTV). The impact of these uncertainties for D90 
and D100 (dose to 90% and 100% of the volume) were 10% and 
19%, respectively.  
Post-implant dosimetry after permanent prostate seed 
implantation is usually based on CT imaging. However, MR 
imaging has superior soft tissue contrast and is some times 
used nowadays. In an interobserver study the dosimetric 
consequence of the delineation uncertainty was estimated to 
be 18% for the prostate D90 when T2 and T1 weighted MR 
images were used. This figure was increased to 23% when the 
delineation was done on CT images. 
Functional MR imaging, such as dynamic-enhanced MR, 
diffusion weighted imaging and MR spectroscopy, gives the 
opportunity to image microenvironmental characteristics of a 
tumour. Specific areas within the target volume with a high 
burden of disease or with biological characteristics indicating 
radioresistance may be targeted for higher dose delivery. 
Even though MR imaging is excellent for target delineation, 
localisation of the applicators (i.e. the source path) or the 
seeds could be challenging. Some applicators (e.g. steel 
applicators or shielded applicators) are not even MR 
compatible. In general it is easier to visualise the applicator 
and source(s) in CT images. For rigid MR compatible 
applicators (e.g. plastic tandem-ring-applicator) so called 
library applicator files could be used. Then applicator file, 
including information about the applicator surface 
dimensions and the source path, can be imported into the MR 
images and rotated and translated until it matches the 
images. In some situations the needle tip could be difficult to 
localise in MR images. Then supplementary imaging could be 
used (e.g. CT) and image registration should be performed 
with the aim of matching the applicator geometry and not 
the bony anatomy. The dosimetric consequences of 
uncertainties in the applicator localisation are smaller 
compared to consequences of uncertainties in the target 
delineation. For the HR CTV D90 an average of 2% change per 
mm displacement of a ring applicator has been found in all 
directions.  
Transrectal US (TRUS) is extensively used in prostate 
brachytherapy and gives an excellent view of the prostate 
gland. However, the presence of needles will preclude the 
image quality. Additionally, localisation of the needle tip 
could be challenging during needle reconstruction. 
TRUS-based brachytherapy procedure offer a method for 
interactive treatment planning and, thus, short time between 
imaging and treatment delivery. Several groups have 
developed methods for “in treatment room” imaging with 
both CT and MR. However, for the latter method, challenges 
due to non MR compatible equipment is substantial. 
   
SP-0034   
Importance of treatment delivery verification 
N . Tselis1 
1Klinikum Offenbach GmbH, Radiation Oncology, Offenbach, 
Germany 
 
Abstract not received. 
 
OC-0035   
Catheter displacement and dosimetry for single fraction 
MRI guided focal prostate HDR brachytherapy 
M. Maenhout1, J.R.N. Van der Voort van Zyp1, M. Peters1, M. 
Van Vulpen1, M.A. Moerland1 
1UMC Utrecht, Department of Radiation Oncology, Utrecht, 
The Netherlands  
 
Purpose/Objective: The aim of this study is to analyze the 
effect of catheter displacement and anatomical variations 
(prostate and organs at risk) on the dose distribution in MRI 
guided single fraction high dose rate (HDR) focal 
brachytherapy of the prostate. 
Materials and Methods: Twenty-two patients were treated 
with MRI guided focal HDR brachytherapy (Iridium-192) in a 
single fraction of 19 Gy. A multiparametric MRI was used to 
define the tumor region and was matched with the 
intraoperative ultrasound (US). For the treatment, self-
anchoring umbrella catheters were used (1). For dose 
